{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:42:45Z","timestamp":1793662965958,"version":"4.5.1"},"reference-count":43,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas"},{"name":"Instituto de Salud Carlos III, Madrid, Spain"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Hepatitis B is a major global health problem with high morbidity and mortality. Approximately 296 million people are living with chronic HBV, and 1.5 million new infections are detected each year, even though a highly effective vaccine has been available for decades and viral replication and transmission can be contained with the use of drugs. Nucleoside therapy, while not curative in most cases, can control viral replication, improve prognosis, and prevent mother-to-child transmission safely. Current treatment guidelines do not include a significant number of chronically infected patients or pregnant women and are often complex to implement. Since these populations continue to have a detectable HVB viral load, they could perpetuate transmission. Expanding and facilitating treatment indications, including treatment as a public health intervention, could help control the spread of the HBV pandemic, thus bringing us closer to the goal of the United Nations General Assembly for the year 2030.<\/jats:p>","DOI":"10.3390\/pathogens12091137","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:07:37Z","timestamp":1693994857000},"page":"1137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is It Time for Treatment as Prevention of Chronic Hepatitis B?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-4124","authenticated-orcid":false,"given":"Jose A.","family":"Perez-Molina","sequence":"first","affiliation":[{"name":"National Reference Centre for Tropical Diseases, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"},{"name":"IRYCIS, Carretera de Colmenar Km 9.1, 28034 Madrid, Spain"},{"name":"CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Infectious Diseases Department, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7113-2471","authenticated-orcid":false,"given":"Marta Rosas","family":"Cancio-Su\u00e1rez","sequence":"additional","affiliation":[{"name":"IRYCIS, Carretera de Colmenar Km 9.1, 28034 Madrid, Spain"},{"name":"Infectious Diseases Department, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"},{"name":"Department of Medicine, Universidad de Alcal\u00e1, Alcal\u00e1 de Henares, 28805 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[{"name":"IRYCIS, Carretera de Colmenar Km 9.1, 28034 Madrid, Spain"},{"name":"CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Infectious Diseases Department, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"},{"name":"Department of Medicine, Universidad de Alcal\u00e1, Alcal\u00e1 de Henares, 28805 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, November 10). Global Hepatitis Report. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1098\/rspb.1993.0102","article-title":"The influence of age on the development of the hepatitis B carrier state","volume":"253","author":"Edmunds","year":"1993","journal-title":"Proc. R. Soc. B Boil. Sci."},{"key":"ref_3","unstructured":"Baeyens, A., and Goffin, T. (2022, December 29). Transforming Our World: The 2030 Agenda for Sustainable Development. Available online: https:\/\/documents-dds-ny.un.org\/doc\/UNDOC\/GEN\/N15\/291\/89\/PDF\/N1529189.pdf?OpenElement."},{"key":"ref_4","unstructured":"World Health Organization (2022, December 10). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf?sequence=1&isAllowed=y."},{"key":"ref_5","unstructured":"World Health Organization (2022, September 21). Global HIV Report. Available online: https:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref_6","unstructured":"Polaris Observatory Collaborators (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol. Hepatol., 3, 383\u2013403."},{"key":"ref_7","unstructured":"WHO (2022, December 29). WHO-UNICEF Estimates of Hepatitis B Vaccination Coverage. Available online: https:\/\/immunizationdata.who.int\/pages\/coverage\/hepb.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.vaccine.2018.03.028","article-title":"Long-term immunity to hepatitis B following vaccination in infancy: Real-world data analysis","volume":"36","author":"Klinger","year":"2018","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.2018.21167","article-title":"HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable","volume":"321","author":"Eisinger","year":"2019","journal-title":"JAMA"},{"key":"ref_11","unstructured":"UNAIDS (2023, February 02). Undetectable = Untransmittable; Public Health and HIV Viral Load Suppression. Available online: https:\/\/www.unaids.org\/en\/resources\/presscentre\/featurestories\/2018\/july\/undetectable-untransmittable."},{"key":"ref_12","unstructured":"Centers for Disease Control and Prevention (2018, December 28). Evidence of HIV Treatment and Viral Suppression in Preventing the Sexual Transmission of HIV, Available online: https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/art\/cdc-hiv-artviral-suppression.pdf."},{"key":"ref_13","unstructured":"Department of Health and Human Services (2022, January 28). Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs during Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.gastha.2022.10.004","article-title":"It Is Time for a Simplified Approach to Hepatitis B Elimination","volume":"2","author":"Dieterich","year":"2023","journal-title":"Gastro Hep Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.1990.03450020082031","article-title":"Sexual Transmission Efficiency of Hepatitis B Virus and Human Immunodeficiency Virus Among Homosexual Men","volume":"264","author":"Kingsley","year":"1990","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/339192","article-title":"Incidence and Risk Factors for Acute Hepatitis B in the United States, 1982\u20131998: Implications for Vaccination Programs","volume":"185","author":"Goldstein","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/OLQ.0000000000001359","article-title":"Incidence and Prevalence of Sexually Transmitted Hepatitis B, United States, 2013\u20132018","volume":"48","author":"Roberts","year":"2021","journal-title":"Sex. Transm. Dis."},{"key":"ref_21","unstructured":"European Centre for Disease Prevention and Control (2022). Annual Epidemiological Report for 2021, ECDC."},{"key":"ref_22","unstructured":"European Centre for Disease Prevention and Control (2016). Epidemiological Assessment of Hepatitis B and C among Migrants in the EU\/EEA, ECDC."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"taab025","DOI":"10.1093\/jtm\/taab025","article-title":"Seroprevalence of vaccine-preventable and non-vaccine-preventable infections in migrants in Spain","volume":"28","author":"Norman","year":"2021","journal-title":"J. Travel Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jtm.12176","article-title":"Point-of-Care Screening, Prevalence, and Risk Factors for Hepatitis B Infection Among 3,728 Mainly Undocumented Migrants From Non-EU Countries in Northern Italy","volume":"22","author":"Pezzoli","year":"2015","journal-title":"J. Travel Med."},{"key":"ref_25","unstructured":"Centers for Disease Control and Prevention (2022, September 21). Viral Hepatitis Surveillance Report\u2014United States, Available online: :https:\/\/www.cdc.gov\/hepatitis\/statistics\/2020surveillance\/index.htm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1537-2995.2006.00974.x","article-title":"Quantification of hepatitis B virus genomes and infectivity in human serum samples","volume":"46","author":"Hsia","year":"2006","journal-title":"Transfusion"},{"key":"ref_27","unstructured":"UK Health Security Agency (2023, September 05). Integrated Guidance on Health Clearance of Healthcare Workers and the Management of Healthcare Workers Living with Bloodborne Viruses (Hepatitis B, Hepatitis C and HIV) UK Advisory Panel for Healthcare Workers Living with Bloodborne Viruses (UKAP), Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1115603\/Integrated-guidance-for-management-of-BBV-in-HCW-November-2022-update.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1743-422X-10-239","article-title":"Medical Virology of Hepatitis B: How it began and where we are now","volume":"10","author":"Gerlich","year":"2013","journal-title":"Virol. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4254\/wjh.v7.i3.488","article-title":"Hepatitis B in healthcare workers: Transmission events and guidance for management","volume":"7","author":"Lewis","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_30","unstructured":"Centers for Disease Control and Prevention (2012). Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. Morb. Mortal. Wkly Rep., 61, 542."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jech.39.2.123","article-title":"Hepatitis B infection in households of acute cases","volume":"39","author":"Goh","year":"1985","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_32","first-page":"1","article-title":"Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B","volume":"8","author":"Roade","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to Chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/cit145","article-title":"Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection","volume":"56","author":"Gatanaga","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","unstructured":"Mizushima, D., Takano, M., Uemura, H., Yanagawa, Y., Aoki, T., Watanabe, K., Gatanaga, H., Kikuchi, Y., and Oka, S. (2020, January 8\u201311). Prophylactic effect of prep against HBV infection among MSM. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. Abstract #1025."},{"key":"ref_36","unstructured":"World Health Organization (2020). Prevention of Mother-to-Child Transmission of Hepatitis B Virus (HBV): Guidelines on Antiviral Prophylaxis in Pregnancy, World Health Organization."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load","volume":"374","author":"Pan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/pd.5452","article-title":"Mother-to-child transmission of hepatitis B virus after amniocentesis: A retrospective matched cohort study","volume":"39","author":"Han","year":"2019","journal-title":"Prenat. Diagn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0168-8278(05)80494-5","article-title":"Failure of neonatal hepatitis B vaccination: The role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates","volume":"20","author":"Grosheide","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06226-0","article-title":"Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: A retrospective longitudinal UK cohort study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/aogs.14448","article-title":"Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis","volume":"101","author":"Yao","year":"2022","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12072-020-10026-0","article-title":"Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: Systematic review and network meta-analysis","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_43","first-page":"S1","article-title":"Tenofovir-DF Therapy Prevents Hepatitis B Vertical Transmission In Highly Viremic Mothers Without HBV Immunoglobulin For Infants","volume":"76","author":"Pan","year":"2022","journal-title":"Hepatology"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/9\/1137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:46:00Z","timestamp":1760129160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/9\/1137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["pathogens12091137"],"URL":"https:\/\/doi.org\/10.3390\/pathogens12091137","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}